Oxford U. study shows aspirin
improves cancer survival by lowers the risk of metastasis 40-50%. This
figure is low, because it includes both short-term usage, and low dose (under
150 mgs.) aspirin. This study is consistent with the Nurse’s Health
Study which found for breast cancer stage I, II, III had a
70% greater survival if they took 2 or more aspirins per week. It was a
long-term study, and far fewer were taking the low-dose aspirin. For Nurses’ Study, Journal of Clinical Oncology,
http://jco.ascopubs.org/content/28/9/1467.abstract
Accepted 12/9/09. All this has
been known for decades (1986 Harvard Nurses study, and 1991 University of
Toronto meta study on colon cancer, to name two on aspirin). Studies say aspirin may help treat or prevent cancer Updated: 18:53, Wednesday, 21 March
2012 http://www.rte.ie/news/2012/0321/aspirin.html -- a large Ireland media
network. {Article at http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2812%2960209-8/abstract?version=printerFriendly, The Lancet, Volume 379,
Issue 9826, Pages 1591-1601, 28 April 2012
doi:10.1016/S0140-6736(12)60209-8} Three
new studies found that taking aspirin may prevent cancer and reduce the
likelihood that cancers will spread to other organs. Three new studies
have added to growing scientific evidence suggesting that taking a daily dose
of aspirin can help prevent, and possibly treat, cancer. However, there remain some concerns about the
drugs side-effects. Previous studies have found that daily aspirin reduces the
long-term risk of death due to cancer, but until now the shorter-term
effects have been less certain, as has the medicine's potential in patients
already diagnosed with cancer. The new
studies, led by Peter Rothwell of
Britain's Oxford University, found that aspirin also
has a short-term benefit in preventing cancer, and that it reduces the
likelihood that cancers will spread to other organs by about 40 to 50%. {There is still the
delay in prevention of about 10 years, but not in improving cancer
survival.—jk} "These
findings add to the case for use of aspirin to prevent cancer, particularly if
people are at increased risk," Mr Rothwell said. "Perhaps more importantly, they also
raise the distinct possibility that aspirin will be
effective as an additional treatment for cancer, to prevent distant spread of
the disease." This was
particularly important, he said, because it is the process of the spread of
cancer, or "metastasis", which most often kills people with the
disease. Aspirin is a cheap
over-the-counter drug generally used to combat pain or reduce fever. It reduces the risk of clots forming in blood
vessels and can therefore protect against heart attacks and strokes. It is often prescribed for people who already
suffer with heart disease and have already had one or several attacks. However, Aspirin also increases the risk of
bleeding in the stomach to around one patient in every thousand per year. This has fuelled an
intense debate about whether doctors should advise patients to take it as
regularly as every day. Last year, a
study by British researchers questioned the wisdom of daily aspirin for
reducing the risk of early death from a heart attack or stroke because they
said the increased risk of internal bleeding outweighed the potential
benefit. Other studies, including some
by Mr Rothwell in 2007, 2010 and 2011, found that an aspirin a day, even at a
low dose of around 75 milligrams, reduces the long-term risk of developing some
cancers, particularly bowel and oesophageal cancer, but the effects don't show until eight to 10
years after the start of treatment. Mr Rothwell, whose
new studies were published in The Lancet and The Lancet Oncology journals, said
this delay was because aspirin was preventing the very
early development of cancers and there was a long time lag between this stage
and a patient having clinical signs or symptoms of cancer. Mr Rothwell and others said deeper
research was now needed into aspirin as a potential treatment for cancer in
patients whose disease has not yet spread.
"No drug has been shown before to prevent
distant metastasis and so these findings should focus future research on
this crucial aspect of treatment," he said. Peter Johnson,
chief clinician at the charity Cancer Research UK, said his group was already
investigating the anti-cancer properties of aspirin. "These findings show
we're on the right track," he said. In a written
commentary on the research in The Lancet, Andrew Chan and Nancy Cook of Harvard
Medical School in the United States said it was "impressive" and
moved health experts "another step closer to broadening recommendations
for aspirin use". ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ |
|
Enter supporting content here
INTERNAL SITE SEARCH ENGINE by Google
Disclaimer:
The information, facts, and opinions
provided here is not a substitute for professional advice. It only indicates
what JK believes, does, or
would do. Always consult your primary
care physician for any medical advice, diagnosis, and treatment. |